BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ren YL, Li TT, Cui W, Zhao LM, Gao N, Liao H, Zhang JH, Zhu JM, Qiao ZY, Guo SC, Pan LL. CD8+ T lymphocyte is a main source of interferon-gamma production in Takayasu's arteritis. Sci Rep 2021;11:17111. [PMID: 34429489 DOI: 10.1038/s41598-021-96632-w] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
Number Citing Articles
1 Danda D, Manikuppam P, Tian X, Harigai M. Advances in Takayasu arteritis: An Asia Pacific perspective. Front Med 2022;9. [DOI: 10.3389/fmed.2022.952972] [Reference Citation Analysis]
2 Matsumoto K, Suzuki K, Yoshida H, Magi M, Kaneko Y, Takeuchi T. Longitudinal monitoring of circulating immune cell phenotypes in large vessel vasculitis. Autoimmun Rev 2022;21:103160. [PMID: 35926769 DOI: 10.1016/j.autrev.2022.103160] [Reference Citation Analysis]
3 Chen R, Wang J, Dai X, Wu S, Huang Q, Jiang L, Kong X. Augmented PFKFB3-mediated glycolysis by interferon-γ promotes inflammatory M1 polarization through the JAK2/STAT1 pathway in local vascular inflammation in Takayasu arteritis. Arthritis Res Ther 2022;24:266. [PMID: 36510278 DOI: 10.1186/s13075-022-02960-1] [Reference Citation Analysis]
4 Rathore U, Thakare DR, Patro P, Agarwal V, Sharma A, Misra DP. A systematic review of clinical and preclinical evidences for Janus kinase inhibitors in large vessel vasculitis. Clin Rheumatol 2021. [PMID: 34729652 DOI: 10.1007/s10067-021-05973-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 11] [Article Influence: 3.5] [Reference Citation Analysis]